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Abstract
Background: Sleep disturbance and insomnia are commonly reported by postmenopausal women. However, the 
relationship between hormone therapy (HT) and sleep disturbances in postmenopausal community-dwelling adults is 
understudied. Using data from the multicenter Study of Osteoporotic Fractures (SOF), we tested the relationship 
between HT and sleep-wake estimated from actigraphy.
Methods: Sleep-wake was ascertained by wrist actigraphy in 3,123 women aged 84 ± 4 years (range 77-99) from the 
Study of Osteoporotic Fractures (SOF). This sample represents 30% of the original SOF study and 64% of participants 
seen at this visit. Data were collected for a mean of 4 consecutive 24-hour periods. Sleep parameters measured 
objectively included total sleep time, sleep efficiency (SE), sleep latency, wake after sleep onset (WASO), and nap time. 
All analyses were adjusted for potential confounders (age, clinic site, race, BMI, cognitive function, physical activity, 
depression, anxiety, education, marital status, age at menopause, alcohol use, prior hysterectomy, and medical 
conditions).
Results: Actigraphy measurements were available for 424 current, 1,289 past, and 1,410 never users of HT. Women 
currently using HT had a shorter WASO time (76 vs. 82 minutes, P = 0.03) and fewer long-wake (≥ 5 minutes) episodes 
(6.5 vs. 7.1, P = 0.004) than never users. Past HT users had longer total sleep time than never users (413 vs. 403 minutes, 
P = 0.002). Women who never used HT had elevated odds of SE <70% (OR,1.37;95%CI,0.98-1.92) and significantly 
higher odds of WASO ≥ 90 minutes (OR,1.37;95%CI,1.02-1.83) and ≥ 8 long-wake episodes (OR,1.58;95%CI,1.18-2.12) 
when compared to current HT users.
Conclusions: Postmenopausal women currently using HT had improved sleep quality for two out of five objective 
measures: shorter WASO and fewer long-wake episodes. The mechanism behind these associations is not clear. For 
postmenopausal women, starting HT use should be considered carefully in balance with other risks since the vascular 
side-effects of hormone replacement may exceed its beneficial effects on sleep.
Background
Sleep in postmenopausal women is altered in ways which
may have an adverse effect on health [1,2]. Explanations
for sleep disturbances that occur during the menopausal
transition and postmenopausal years include nocturnal
hot flashes, mood disorders, and sleep disordered breath-
ing [3-6]. Postmenopausal hormone therapy (HT) has
been the standard treatment for many menopausal com-
plaints, including hot flashes and insomnia [7-11]. How-
ever, given the large number of postmenopausal women
experiencing sleep disturbance after the menopausal
transition [12-14] and the consequences of poor sleep on
daytime functioning, the relationship between HT and
objectively measured sleep in older postmenopausal
women needs further study.
Clinical and experimental studies offer compelling evi-
dence that exogenous administration of sex hormones
regulates many brain functions that are involved in the
regulation of sleep [15-17]. Increased estrogen levels have
been hypothesized to improve sleep by shortening sleep
latencies [18]; reducing nocturnal restlessness and night-
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time awakenings [11,19]; decreasing movement arousals
[7]; improving sleep efficiency [20]; and increasing REM
sleep [8,21,22]. Estrogen replacement has also been
shown to reduce sleep disordered breathing in postmeno-
pausal women [23,24] while exogenous administration of
progestin produces sedative effects in both women and
men [25,26]. Estrogen and progestin both improve vaso-
motor symptoms and may be beneficial for sleep distur-
bance [27,28]. Estrogen alone [7], but not estrogen plus
progestin [29], alleviated the frequency of nocturnal
movement arousals as measured by polysomnography.
Given that data on the effects of estrogen on sleep quality
(e.g. total sleep time, sleep efficiency, number of awaken-
ings, wake after sleep onset, and sleep latency) in post-
menopausal women are sparse, there is a clear need for
contemporary research to clarify the inconsistency.
In this study, we examined data gathered in the Study of
Osteoporotic Fractures (SOF), a longitudinal cohort
study designed to examine the risk factors of osteoporotic
fractures in women, to test the hypothesis that HT in
postmenopausal women is associated with better sleep
measured objectively by wrist actigraphy. This study pop-
ulation provides a unique opportunity to examine this
question in a large community-dwelling cohort of post-
menopausal women, with additional data collected to
allow for adjustment of possible confounders.
Methods
Participants
The SOF is a longitudinal epidemiologic study of 10,366
women age 65 years or older, recruited from four study
centers located in Baltimore, MD; Minneapolis, MN;
Portland, OR; and the Monongahela Valley near Pitts-
burgh, PA. Women were excluded if they had a bilateral
hip replacement or were unable to walk without assis-
tance. The baseline SOF examinations were conducted
from 1986-88, when 9,704 Caucasian women were
recruited [30]. SOF was originally designed to investigate
risk factors for osteoporosis and osteoporotic fractures,
and initially African-American women were excluded
from the study due to their low incidence of hip fractures,
but from February 1997 to February 1998 662 African-
American women were enrolled. At all subsequent visits,
no exclusion criteria were used. All participants were
community-dwelling at baseline. Since then follow-up
exams have taken place approximately every two years.
The focus of this analysis was data gathered at the SOF
year 16 or visit 8, which took place between January 2002
and February 2004. Of the 4,727 women at this visit, wrist
actigraphy data were collected on 3,676 (78%) partici-
pants with clinic or home visits. Of the sample with wrist
actigraphy, a total of 3,123 (85%) women had technically
adequate actigraphy data and HT data available. Among
these there were 424 current HT users, 1,289 past HT
users, and 1,410 never HT users. The institutional review
boards on human research approved the study at each
institution, and all participating women provided written
informed consent.
Actigraphy
Participants wore the Sleep-watch-O (SleepWatch-O®,
Ambulatory Monitoring, Inc) actigraph, a small, vali-
dated device worn on the wrist for highly effective sleep-
wake inference from wrist activity [31,32]. Movement is
measured by a piezoelectric linear accelerometer (sensi-
tive to 0.003 g and above), which generates a voltage each
time the actigraph is moved. These voltages are gathered
continuously and summarized over 1-minute epochs.
The actigraph collects movement data in 3 different
modes; zero crossings mode (ZCM), time above thresh-
old mode (TAT), and proportional integration mode
(PIM). Data from the PIM mode was used in this analysis
b e c a u s e  i t  c o r r e s p o n d e d  b e s t  t o  t h e  g o l d  s t a n d a r d  o f
polysomnography (PSG) for estimation of sleep and wake
in our population [33]. The actigraph was initialized in
the clinic prior to the visit, and placed on the participant's
nondominant wrist by the examiner during the visit.
Women wore the actigraphs continuously for a minimum
of three 24-hour periods (i.e., 72 hours). The average of
the sleep parameters over all nights was used in this anal-
ysis to minimize interdaily variability. In general, scoring
of actigraphy data was very reliable and highly predictive
of total sleep time as measured by PSG [33].
ActionW-2 software (Ambulatory Monitoring, Inc.)
was used to score the sleep and wake periods and com-
pute sleep variables. All participants completed a daily
sleep log which was used to edit the actigraphs data. The
UCSD sleep scoring algorithm available in this software
was used to differentiate sleep from wake for the PIM
mode data. This algorithm calculates a moving average,
which takes into account the activity levels immediately
before and after the current minute to determine if the
timepoint should be coded as sleep or wake. The follow-
ing sleep parameters were calculated: Total sleep time
(TST) as the mean minutes scored as nighttime sleep
while in-bed; Sleep efficiency as the percentage of time
(0-100%) the participant was sleeping while in-bed; Sleep
latency as the number of minutes from the time the par-
ticipant reported getting into bed to sleep onset as scored
on the actigraph, defined as the when the participant
achieved sleep for 20 continuous minutes after getting
into bed; Wake after sleep onset (WASO) as the number
of minutes scored as awake from sleep onset to the end of
the last sleep episode while in-bed; Number of long-wake
episodes defined as ≥ 5 minutes duration; Napping
behavior was estimated as the total time while the partic-
ipant was not in bed at night that was scored as sleepingTranah et al. BMC Women's Health 2010, 10:15
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by the sleep-scoring algorithm (this may include periods
of extreme inactivity).
S l e e p  p a r a m e t e r s  w e r e  a n a l y z e d  b o t h  a s  c o n t i n u o u s
measures and as categorical exposure variables based on
current beliefs about clinically relevant values of sleep
parameters in older adults. Total sleep time was catego-
rized as <6 hours, 6-8 hours and >8 hours. Sleep effi-
ciency was categorized as <70% and ≥ 70%. Sleep latency
was categorized as <60 minutes and ≥ 60 minutes. WASO
was categorized as <90 minutes and ≥ 90 minutes. Num-
ber of long-wake episodes was categorized as <8 and ≥ 8.
Napping was categorized as <2 hours and ≥ 2 hours.
Postmenopausal Hormone Use
Participants were asked about HT at every follow-up visit
approximately every two years for 16 years up to this visit.
Women were divided into three HT groups: never users;
past users (stopped use prior to Visit 8); current users
(used at Visit 8). Long versus short term current HT was
examined by analyzing associations for participants using
HT for ≤ 5 (n = 86) and >5 years (n = 338). Among past
HT users, associations among those stopping ≤ 5 (n =
454) and >5 (n = 835) years ago were examined.
Other Measurements
All participants completed questionnaire data, which
included questions about medical history, self-reported
health, smoking status, alcohol use, marital status, and
whether or not the participant walked for exercise. The
Geriatric Depression Scale (GDS) was used to assess
depressive symptoms with the standard cutoff of ≥ 6
symptoms used to define depression. Anxiety was
assessed using the Goldberg Anxiety Scale. During the
home or clinic visits current medication use within the
last 2 weeks was assessed by examination of medications,
and a computerized medication coding dictionary was
used to categorize these medications. The Mini-Mental
State Examination (MMSE) was administered to assess
cognitive function, with higher scores on a scale of 0 to 30
representing better cognition. Physical activity was
assessed by asking participants how many blocks they
normally walked for exercise per day. Body weight and
height were measured, and body mass index (BMI) was
calculated as Kg/m2.
Statistical analysis
Characteristics known to be related to HT were summa-
rized using means and SDs for continuous data and per-
centages for categorical data. To identify potential
confounders, we considered a list of predictors thought to
be associated with HT and sleep parameters based on
biological plausibility or previous studies including age,
clinic site, race, BMI, anxiety, depression, cognitive func-
tion, alcohol use, smoking status, education, marital sta-
tus, self-reported health status, physical activity,
antidepressant use, prior hysterectomy, and medical con-
ditions (cardiovascular disease, cancer, hypertension and
diabetes). We compared characteristics between current,
past and never HT users using 3-way ANOVA for contin-
uous covariates and chi square tests for categorical data.
All assumptions of the ANOVA model were tested and p-
values were calculated using the Wilcoxon non-paramet-
ric test for skewed covariates. To assess potential con-
founding we performed univariate tests to determine the
association between the each of the sleep variables and
the covariates. Variables that were significantly related (p
< 0.10) to at least one sleep outcome measure and HT
were included in the final multivariate analyses. To deter-
mine the relationship between HT and continuous mea-
sures of sleep parameters in the multivariate analysis, we
compared the adjusted means across the 3 categories
using ANOVA pairwise tests from generalized linear
models. Analyses were performed in which propensity
scores were calculated indicating the likelihood of HT use
based on a ordinal logistic regression model with HT as
the outcome adjusted for the covariates in the multivari-
ate model [34]. This propensity score was then used in
place of the covariates in the models. Because use of pro-
pensity scores did not substantially alter the findings
regarding the association between HT and likelihood of
sleep disturbances, models adjusted for multiple covari-
ates are presented in this article. Multinomial logistic
regression models were also used to examine the relation-
ship between HT and categorized sleep parameters. We
modeled the odds of sleep disturbance for the following
categories: sleep efficiency <70% compared with ≥ 70%;
sleep latency ≥ 60 minutes compared with <60 minutes
and; WASO ≥ 90 minutes compared with <90 minutes;
number of long-wake episodes ≥ 8 compared with <8;
and napping ≥ 2 hours compared with <2 hours. Polyto-
mous logistic regression was used to simultaneously esti-
mate the odds of total sleep time <6 hours and >8 hours
compared with 6-8 hours. Statistical analysis was per-
formed using the statistical software program SAS ver-
sion 9.1 (SAS Institute, Inc., Cary, NC).
Results
Characteristics of the study population
The analysis cohort for this study was composed of 3,123
women (mean age 84 ± 4 years, range 77-99 years) with
actigraphy measurements. We previously compared the
overall distribution of subject characteristics and health
conditions of the 3,123 women with wrist actigraphy to
the 1,795 who did not have actigraphy measured [35].
The latter group was on average 1.4 years older, had
higher rates of IADL impairment and stroke, had a worse
mean depression score, lower cognitive functioning, and
were more likely to be diagnosed with Alzheimer's dis-Tranah et al. BMC Women's Health 2010, 10:15
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ease. This group also and experienced an almost 2-fold
increased mortality rate compared to women with actig-
raphy measurements.
Among the 3,123 women with wrist actigraphy, there
were 424 current HT users, 1,289 past HT users, and
1,410 never HT users (Table 1). Current HT users were
slightly younger and more likely to be married, have a
higher education, exercise more, have better cognitive
function, have had a hysterectomy when compared to
both other groups. Never HT users were more likely to be
African American, have a higher BMI and more medical
conditions when compared to both other groups. Past
HT users were more likely to have higher anxiety scale
sores when compared to both other groups. Both current
and past HT users were more likely to be diagnosed with
depression when compared to never users. The majority
of current HT users were taking conjugated estrogens
(88%) including Premarin (62%) and Prempro (5%).
Approximately 15% of current HT users were taking
estrogen and progestin.
HT and sleep
Women currently taking HT compared to never users
were less likely to have their sleep interrupted by waking
after falling asleep (Table 2), as indicated by fewer long-
wake (≥ 5 minutes) episodes (6.5 vs. 7.1, P = 0.004) and
less WASO time (76 vs. 82 minutes, P = 0.03) after adjust-
ment for multiple potential confounders (age, clinic site,
race, BMI, anxiety, depression, cognitive function, alco-
hol use, education, marital status, self-reported health
status, number of blocks walked for exercise per day,
prior hysterectomy and medical conditions). Sleep
latency did not differ across the groups, nor did sleep effi-
ciency or napping. Past HT users had significantly more
total sleep time than never users (413 vs. 403 minutes, P =
0.002). Among current HT users, length of usage (≤ 5 and
>5 years) and among past HT users, time since stopping
did not influence group differences in sleep indicators
(data not shown).
Compared to current HT users, women who never
used HT had significantly higher odds of ≥ 8 long-wake
episodes (odds ratio (OR), 1.58; 95% confidence interval
(CI), 1.18-2.12; p = 0.002) and wake after sleep onset ≥ 90
minutes (OR, 1.37; 95% CI, 1.02-1.83; p = 0.03) (Table 3).
Not statistically significant were higher odds of low sleep
efficiency <70% (OR, 1.37; 95% CI, 0.98-1.92) and nap-
ping ≥ 2 hours (OR, 1.35; 95% CI, 0.94-1.92) (Table 3).
Odds of having lower total sleep time or higher sleep
latency were not different across the groups. There was
no effect of progestin use or duration of HT use on the
results and results did not differ when estrogen+proges-
tin users were excluded from the analysis.
Discussion
To our knowledge, this is the first study in older, commu-
nity-dwelling postmenopausal women that has evaluated
the relationship between long-term HT and objectively
measured sleep. These results are consistent with find-
ings from a large number of epidemiological studies that
support a relationship between HT and improved sleep
characteristics [1,2]. A limited number of studies includ-
ing menopausal women not reporting vasomotor symp-
toms have demonstrated that HT use relieved insomnia
[11] and reduced sleep disturbance [27], suggesting a
mechanism independent of hot flashes. A placebo-con-
trolled study of HT in postmenopausal women reported
decreased wakefulness after sleep onset, and increased
total sleep time after the initiation of HT and enhanced
REM sleep [21]. Another comparison of placebo with HT
showed a reduction in the number of sleep-disordered
breathing episodes and a decreased duration of hypo-
pneas with HT [24].
Sleep difficulties in older postmenopausal women may
be influenced by the emergence of coexisting medical
conditions and the presence of other hormonal, physio-
logic, and even psychosocial factors [36-38]. Estrogen
regulates the synthesis and release of neurotransmitters
and neuromodulators that affect many brain functions
including mood, behavior, cognition and sleep [15-
17,21,39,40]. For example, the serotonergic system is reg-
ulated by ovarian steroids and by estrogen and progester-
one treatment [39]. In addition, sex hormone receptors
are present in the suprachiasmatic nucleus (SCN) [41],
the key biologic clock in the brain that orchestrates circa-
dian biological rhythms, such as the rhythms of hor-
mones, body temperature, sleep and mood. These
experimental findings may provide a potential neuroen-
docrine mechanism by which HT can act to improve
SCN-related rhythm disturbances, such as body tempera-
ture, mood and sleep [41].
A small number of observational studies [5,42,43] have
examined the role of HT in preventing or alleviating
sleep-disordered breathing (SDB), which is more com-
mon among postmenopausal women and may be a con-
founder in the present analysis. This is also an important
consideration since wrist actigraphy may underestimate
arousal/fragmentation index and WASO as measured by
PSG in severe obstructive sleep apnea patients [44]. One
small study [42] found that postmenopausal women tak-
ing HT had a lower prevalence of SDB compared with
postmenopausal women not taking HT (based on fewer
than 30 women with SDB). The presence of SDB in this
study appeared to be associated exclusively with obesity
and controlling for age and BMI attenuated the associa-
tion between HT and SDB [42]. A second study [43]
found that HT users had lower odds of SDB but that con-
trolling for BMI removed the association between meno-Tranah et al. BMC Women's Health 2010, 10:15
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Table 1: Visit 8 characteristics among postmenopausal hormone therapy (HT) categories from the SOF Cohort.
Characteristics Current Past Never
(N = 424) (N = 1,289) (N = 1,410) P-value*
Age (y), mean +/- SD 82.9 +/- 3.4 83.8 +/- 3.4 83.6 +/- 4.2 0.0002
Body mass index (kg/m2), mean +/- SD 26.2 +/- 4.6 26.6 +/- 4.7 27.7 +/- 5.3 <.0001
Married, n (%) 149 (35.2) 378 (29.4) 299 (21.2) <.0001
African-American, n (%) 34 (8.0) 29 (2.3) 265 (18.8) <.0001
Clinic site, n +/- SD <.0001
BALTIMORE 70 (16.5) 238 (18.5) 240 (17.0)
MINNEAPOLIS 131 (30.9) 464 (36.0) 422 (29.9) <.0001
PITTSBURGH 49 (11.6) 280 (21.7) 537 (38.1) <.0001
PORTLAND 174 (41.0) 307 (23.8) 211 (15.0) <.0001
Education (y), mean +/- SD 13.3 +/- 2.6 13.1 +/- 2.6 12.4 +/- 2.8 <.0001
Age at menopause, mean +/- SD 47.7 +/- 6.4 48.5 +/- 5.6 47.9 +/- 5.9 0.0181
Years of menopause, mean +/- SD 34.6 +/- 6.9 35.2 +/- 6.5 34.6 +/- 7.6 0.3451
Any alcohol intake in the past 30 days, n (%) 188 (44.4) 583 (45.3) 514 (36.5) <.0001
Current smoker, n (%) 10 (2.4) 32 (2.5) 43 (3.1) 0.593
Self-reported health status, n (%) 0.4438
Poor/very poor 7 (1.7) 28 (2.2) 36 (2.6)
Fair 88 (20.8) 275 (21.4) 330 (23.4) 0.4438
Good/excellent 328 (77.5) 984 (76.5) 1044 (74.0) 0.4438
Medical condition (0-4) 1.2 +/- 0.9 1.3 +/- 1.0 1.3 +/- 0.9 0.1621
Goldberg Anxiety Scale score, mean +/- SD 1.3 +/- 2.2 1.5 +/- 2.3 1.2 +/- 2.1 0.0007
Geriatric Depression Scale score, mean +/- SD 2.2 +/- 2.3 2.5 +/- 2.6 2.4 +/- 2.7 0.0157
Diagnosed with depression 124 (8.81) 185 (14.35) 64 (15.13) <.0001
MMSE score, mean +/- SD 28.1 +/- 1.7 28.0 +/- 2.0 27.7 +/- 2.1 <.0001
Walks for exercise (yes), n (%) 182 (43.2) 487 (38.3) 479 (34.4) 0.0028
Blocks walked for exercise (daily), mean +/- SD 9.8 +/- 12.2 8.14 +/- 9.9 7.5 +/- 9.7 0.0072
Currently taking antidepressants, n (%) 43 (10.1) 119 (9.2) 104 (7.4) 0.0984
Current sleep medication user, n (%) 1 (0.2) 26 (2.0) 8 (0.6) 0.0003
Prior hysterectomy, n (%) 285 (67.4) 551 (42.9) 409 (29.0) <.0001
* Values of p for continuous data are from a t test for normally distributed data and a Wilcoxon rank sum test for skewed data. Values of p for 
categorical data are from a chi-squared test test for homogeneity.
SOF = Study of Osteoporotic Fractures; MMSE = Mini-Mental State Examination; SD = standard deviation.
pause and SDB. A third study [5] identified a reduced risk
of SDB among HT users and that the association
remained significant after adjustment for determinants of
SDB. These data combined suggest that menopause is a
significant risk factor for SDB in women and that HT
appears to be associated with reduced risk. However, it
should be noted that age and BMI are significant risk fac-
tors for SDB and that the inverse relationship between
HT and SDB was weakest among the oldest age group ≥
70 years [5,42], which is similar to the age group in the
current study.
Several methodologic and etiologic factors may be con-
tributing to the inconsistent associations previously
reported for HT and sleep, including differences in study
population, hormone formulation and dose, and duration
of study [7,8,21,29]. In this study, current HT users had a
higher education, exercised more, had fewer medical
conditions and better cognitive function but were also
more likely to be diagnosed with depression compared to
past and never postmenopausal hormone users. Multi-
variate adjustment suggests that the association of HT
with improved sleep is independent of these factors.
However, it is possible that HT may have no direct causalTranah et al. BMC Women's Health 2010, 10:15
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association with sleep improvement and may be influenc-
ing other age-related factors that are benefiting sleep but
are not accounted for in our analysis. We found no sleep
quality differences between those participants currently
using HT for ≤ 5 and >5 years or between past HT users
who stopped ≤ 5 and >5 years prior to this study. HT for-
mulations are not uniform and consist of various estro-
gen and progestin combinations and doses that may lead
to differential effects on sleep. In this study, results did
not differ when estrogen and progestin users were
excluded from the analysis. However, as there were fewer
than 80 progestin users among the SOF participants with
wrist actigraphy, progestin use could still be a potential
confounder of this relationship.
Our study had a number of strengths, including a large
cohort of community-dwelling postmenopausal women
with no inclusion requirements regarding sleep disorders.
Several different sleep parameters were examined, all of
which were gathered objectively, and there were extensive
data for adjustment of possible confounders. To avoid any
misclassifications of HT usage prior to actigraphy, mea-
surements of HT usage were collected approximately
Table 2: Associations between postmenopausal hormone therapy (HT) and sleep parameters.
HT use
Parameter Current Past Never
(N = 424) (N = 1,289) (N = 1,410)
Total sleep time, minutes (SD) 407 (5) 413 (4) 403 (4)a
Sleep efficiency, % (SD) 77.3 (0.8) 76.9 (0.7) 76.1 (0.6)
Sleep latency, minutes (SD) 41.4 (2.7) 43.5 (2.2) 44.7 (2.2)
Wake after sleep onset, minutes (SD) 76.0 (3.3) 79.1 (2.7) 82.1 (2.7)b
Long wake episodes, # (SD) 6.5 (0.2) 6.9 (0.2)b 7.1 (0.2)c
Napping, minutes (SD) 77.1 (4.5) 80.0 (3.7) 80.5 (3.6)
a P < 0.01 vs. Past HT use
b P < 0.05 vs. Current HT use
c P < 0.01 vs. Current HT use
Adjusted for age, clinic site, race, BMI, cognitive function, number of blocks walked for exercise per day, depression, anxiety, education, 
marital status, age at menopause, alcohol use, prior hysterectomy and medical conditions.
Table 3: Associations between postmenopausal hormone therapy (HT) and categorized sleep parameters.
HT use
Parameter Current Past Never
(N = 424) (N = 1,289) (N = 1,410)
Total sleep time <6 hoursa 1.00 (Ref.) 0.99 (0.85 - 1.15) 1.14 (0.85 - 1.53)
>8 hoursa 1.00 (Ref.) 1.17 (0.97 - 1.40) 1.02 (0.69 - 1.51)
Sleep efficiency <70%b 1.00 (Ref.) 1.03 (0.87 - 1.21) 1.37 (0.98 - 1.92)
Sleep latency >= 60 minutesc 1.00 (Ref.) 1.06 (0.90 - 1.25) 1.15 (0.82 - 1.60)
Wake after sleep onset >= 90 minutesd 1.00 (Ref.) 1.03 (0.90 - 1.19) 1.37 (1.02 - 1.83)
Long wake episodes >= 8e 1.00 (Ref.) 1.10 (0.95 - 1.27) 1.58 (1.18 - 2.12)
Napping >= 2 hoursf 1.00 (Ref.) 1.13 (0.95 - 1.34) 1.35 (0.94 - 1.92)
a Compared with 6-8 hours
b Compared with ≥ 70%
c Compared with <60 minutes
d Compared with <90 minutes
e Compared with <8 episodes
f Compared with <2 hours
Adjusted for age, clinic site, race, BMI, cognitive function, number of blocks walked for exercise per day, depression, anxiety, education, 
marital status, age at menopause, alcohol use, prior hysterectomy and medical conditions.Tranah et al. BMC Women's Health 2010, 10:15
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every two years for 16 years. For this analysis, it is likely
that hot flashes were uncommon in the study participants
who were 77-99 years at the sleep exam. This analysis also
had several limitations. We are unable determine causal-
ity since actigraphy was collected at a single time and we
cannot rule out that previous sleep problems influenced
HT usage. Findings are for older women, with a mean age
of 84 ± 4 years (range 77-99 years) and may not be gener-
alizable to younger women undergoing menopause. We
adjusted for education as a surrogate for SES but this may
be an inadequate measure of SES in this cohort of elderly
women. The individuals who had actigraphy were some-
what healthier than those who did not have these mea-
sures, and thus, it is possible that different associations
may have been observed with inclusion of these women.
The lack of PSG limits our ability to account for sleep
apnea in these analyses. Lastly, confounding by unknown
or other unmeasured confounding factors could have
resulted in biased estimates of effect.
Conclusions
Our findings suggest that postmenopausal women cur-
rently using HT had improved sleep quality for two out of
five objective measurements. Both measures, shorter
WASO and fewer long-wake episodes, are specifically
related to sleep fragmentation. The mechanism behind
this association is not clear but multivariate adjustment
suggests that the beneficial effects of HT are not
explained by other behavioral, aging- and health-related
variables. While the majority of women start HT to
relieve menopausal symptoms, some continue to use HT
beyond the menopausal transition. In this study 14% of
participants were using HT at the 16th year of the SOF
(mean age of 83 ± 4 years). For an individual postmeno-
pausal woman, however, starting HT use should be con-
sidered carefully in balance with other risks since the
vascular side-effects of hormone replacement may exceed
its beneficial effects on sleep [45-47].
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